Brief: UCB Presents Data On Bepranemab In Early Alzheimer's Disease In Phase 2A Study

UCB SA

31/10/2024 17:06

Oct 31 (Reuters) - Ucb SA  UCB.BR :
    * UCB PRESENTS ENCOURAGING DATA ON BEPRANEMAB IN EARLY
ALZHEIMER’S
DISEASE IN PHASE 2A STUDY AT CTAD 2024
    * RESULTS PROVIDE FIRST EVIDENCE OF BIOLOGICAL AND CLINICAL
EFFECT
OF A MID-DOMAIN TAU-TARGETING DISEASE-MODIFYING THERAPY
    * IS EVALUATING NEXT STEPS IN DEVELOPMENT PROGRAM

Source text:  ID: 
Further company coverage:  UCB.BR 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))